Hip Resurfacing — Cost, Top Hospitals & Success Rates | MyMedicPlus

Hip resurfacing arthroplasty (HRA) is a bone-conserving alternative to conventional total hip replacement (THA) in which the femoral head is not removed but instead reshaped and capped with a cobalt-chromium alloy shell, articulating against a matching metal acetabular cup. Unlike total hip arthroplasty — where the entire femoral head and neck are replaced with a stemmed femoral prosthesis — hip resurfacing preserves the femoral neck and proximal femoral metaphysis, providing a more anatomical reconstructed joint and potentially simplifying any future revision to conventional THA.

The concept of hip resurfacing dates to the 1970s and 1980s, when early designs using polyethylene bearings failed due to catastrophic wear and osteolysis. The modern era of hip resurfacing was established with the development of the Birmingham Hip Resurfacing (BHR) system by Derek McMinn in Birmingham, UK, in 1997. The BHR introduced a large-diameter metal-on-metal (MoM) articulation with improved manufacturing tolerances, achieving wear rates far below earlier polyethylene-bearing designs and delivering excellent early-to-medium-term registry results.

The theoretical advantages of hip resurfacing over conventional THA include: (1) preservation of proximal femoral bone stock, simplifying potential future revision; (2) use of large femoral head sizes (typically 44–56 mm) providing a large range of motion before impingement and substantially lower dislocation risk than small-head conventional THA; (3) restoration of more normal hip biomechanics with preserved femoral offset and neck length; and (4) potential for higher activity levels due to joint stability.

However, the story of hip resurfacing has been profoundly complicated by the recognition, from approximately 2008 onward, that all metal-on-metal articulations generate cobalt and chromium ion particles and nanoparticles through tribocorrosion at the articulating surfaces and at the modular head-neck taper junction. This has led to regulatory alerts, mandatory surveillance programs, and the withdrawal from market of most resurfacing devices. As of 2026, hip resurfacing remains available for highly selected patients primarily through the BHR device, but requires careful pre-implant counseling, strict patient selection, and lifelong post-implant monitoring.

Hip resurfacing is indicated for a narrow and carefully defined subset of patients with end-stage hip arthritis for whom the specific advantages of bone conservation, large-head stability, and activity potential outweigh the acknowledged risks of metal-on-metal articulation. The primary conditions considered for resurfacing are:

Primary Osteoarthritis in Young Active Males: The ideal resurfacing candidate is a young (under 55–60 years), physiologically fit, active male with primary hip OA, large femoral head size (>48–50 mm), and excellent bone quality. In this specific population, the BHR demonstrates 10-year survivorship rates of 95–97% — competitive with the best conventional THA outcomes — while preserving bone stock for the potential future revision that is statistically likely given the patient's life expectancy.

Osteonecrosis (AVN) — With Caveats: Early-stage avascular necrosis (Ficat stage II–III) before femoral head collapse has been treated with resurfacing in selected patients with adequate viable bone stock, particularly in young patients where preserving the femoral neck for future revision is valuable. However, advanced osteonecrosis with significant femoral head collapse (Ficat stage III–IV), large necrotic lesions (>30–40% of femoral head volume), or involvement of the femoral neck is a contraindication to resurfacing — inadequate bone stock risks component loosening and femoral neck fracture. Conventional THA is preferred in most AVN cases.

Conditions Where Resurfacing Is NOT Appropriate:

• Female patients — female patients have a significantly higher rate of adverse reactions to metal debris (ARMD), pseudotumor formation, and early revision after MoM resurfacing. Multiple registry analyses and systematic reviews confirm that women have 2–3 times higher revision rates than men with the same devices. Most guidelines now recommend against MoM resurfacing in female patients.
• Patients with femoral neck deformity, cysts, or prior osteotomy affecting femoral neck geometry — inadequate bone stock risks femoral neck fracture during or after surgery
• Patients with renal impairment — cobalt and chromium clearance is reduced, leading to higher blood ion accumulation
• Patients with known metal hypersensitivity (cobalt, chromium, or nickel allergy) — MoM articulation is contraindicated
• Small femoral head size (components smaller than 46–48 mm) — small MoM components have disproportionately higher wear rates due to edge loading geometry
• Active inflammatory arthropathy — bone quality and healing are compromised

Strict patient selection is the most critical factor determining safety and success with hip resurfacing. The following criteria constitute the evidence-based framework for appropriate candidate identification.

Ideal Candidate Profile:

• Sex: Male — female patients have substantially higher ARMD and revision rates with all MoM devices
• Age: Under 55–60 years, though physiological fitness is more relevant than chronological age
• Femoral head size: Large — component sizes of 48 mm or greater; small components (<46 mm) should not receive MoM resurfacing
• Bone quality: Excellent — no significant osteoporosis (DEXA T-score above -1.5), no large femoral head cysts (<1 cm), no prior radiation to the pelvis, no metabolic bone disease
• Activity level: High — a patient who wants to return to high-demand physical activities (skiing, long-distance hiking, manual labor) where the stability advantage of resurfacing is most clinically meaningful
• Renal function: Normal — eGFR above 60 mL/min/1.73m2; cobalt and chromium are renally cleared, and impaired renal function leads to ion accumulation
• No metal hypersensitivity: No known allergy to cobalt, chromium, or nickel; skin patch testing is recommended if allergy history is uncertain

Preoperative Workup for Resurfacing Candidates:

• Plain radiographs with templating — to confirm femoral head size, exclude cysts, assess acetabular coverage
• CT scan with 3D reconstruction — to evaluate femoral neck geometry, component sizing, and anteversion planning
• Renal function (eGFR) and baseline cobalt/chromium blood levels (blood ions should be below 2 ppb at baseline)
• DEXA bone density scan in patients over 45 years or with risk factors for osteoporosis
• Allergy history and patch testing if metal sensitivity is suspected

Informed Consent Requirements for Hip Resurfacing: Candidates must receive comprehensive counseling about: (1) the metal-on-metal nature of the bearing and its known potential for ion release; (2) the MHRA and FDA monitoring requirements; (3) the need for lifelong annual ion surveillance; (4) the specific signs of ARMD to report immediately; (5) the higher revision rates compared to optimal conventional THA in the published registry literature; and (6) the option of conventional THA as an alternative with more established long-term data. Informed consent for resurfacing should be documented more thoroughly than for standard THA.

The most widely used and best-evidenced hip resurfacing system is the Birmingham Hip Resurfacing (BHR), developed by Derek McMinn and commercialized by Smith+Nephew. The BHR comprises a cobalt-chromium femoral component (a hollow mushroom-shaped cap cemented onto the prepared femoral head) and a press-fit cobalt-chromium acetabular cup with a highly polished inner surface. The bearing articulation is large-diameter cobalt-chromium-on-cobalt-chromium metal-on-metal.

Surgical Technique: The BHR is typically performed through a posterior or posterolateral approach with the patient in the lateral decubitus position. A key technical requirement is precise femoral component positioning — the femoral component must be placed with accurate varus-valgus alignment (within 5 degrees of neutral) and appropriate anteversion to minimize edge loading of the cup, which dramatically increases ion generation. Malpositioning is the dominant technical cause of early ARMD and elevated blood ions.

Femoral Preparation: The femoral head is preserved and shaped using a series of reamers and cutting guides to create the exact taper for the femoral component. Copious irrigation is used to remove bone debris. The prepared femoral head is cemented with polymethylmethacrylate (PMMA) bone cement, achieving immediate rigid fixation while preserving the femoral neck for potential future conversion to THA.

Acetabular Cup Placement: The acetabular cup is implanted cementless using press-fit with hydroxyapatite surface coating, positioned at 40 degrees of inclination and 15–25 degrees of anteversion — the combined anteversion of cup and femoral component should reach approximately 40–45 degrees total. Cup malposition (excessive inclination or retroversion) is the most common cause of edge loading, elevated metal ion generation, and early failure.

Head Sizes and Bearing Characteristics: BHR head sizes range from 38 to 60+ mm in 2 mm increments. The large bearing diameter provides substantially greater range of motion before femoral neck impingement on the cup rim compared to small-head conventional THA, and the jump distance (force required to dislocate the joint) is correspondingly higher — explaining the low dislocation rates of resurfacing versus conventional THA.

Other Resurfacing Devices: The Conserve Plus (Wright Medical) and ADEPT (Finsbury Orthopaedics) systems use similar MoM principles to the BHR. The Durom (Zimmer Biomet) was withdrawn from the US market in 2008 following elevated early failure rates. Most comparative registry analyses identify the BHR as having the best long-term survivorship among available resurfacing devices, making it the preferred choice when resurfacing is clinically indicated.

In carefully selected patients — primarily young active males with large femoral heads and excellent bone stock — hip resurfacing offers specific advantages over conventional THA that must be weighed against the metal-on-metal risks described in the risks section below.

Bone Stock Preservation: The most clinically significant advantage of resurfacing is preservation of the proximal femoral bone. Because no femoral stem is implanted, the femoral canal, metaphysis, and femoral neck remain intact and available for future implant fixation. This substantially simplifies conversion to conventional THA if revision becomes necessary — it is technically a moderately complex revision rather than a complex reconstruction requiring long-stem revision implants. This matters enormously for a 45-year-old patient who may require 2–3 hip operations in a lifetime.

Very Low Dislocation Rate: The large femoral head size (44–56 mm) of hip resurfacing produces a dislocation rate of less than 1% — compared to 1–3% for conventional primary THA. This stability advantage is meaningful for active patients who wish to participate in sports and physical activities that impose impingement-risk positions. Postoperative dislocation precautions are less stringent than with small-head conventional THA.

Preserved Proximal Femoral Biomechanics: Conventional THA with a femoral stem bypasses the proximal femur, resulting in stress shielding of the calcar and proximal femur that can lead to periprosthetic bone loss over time. Resurfacing transmits forces through the preserved femoral neck and proximal metaphysis in a more physiological pattern, potentially reducing stress shielding osteolysis.

Registry Survivorship in Optimal Patients: The NJR (UK) 10-year data for BHR in males with femoral head sizes 50 mm or larger shows survivorship of 95–97% — among the best outcomes of any hip arthroplasty device in the registry. The AOANJRR similarly reports BHR survivorship competitive with leading conventional THA systems in appropriately selected males. These survival rates represent real-world performance in the national surveillance system, not selected trial populations.

Return to High-Demand Activity: Resurfacing patients have historically reported higher post-operative activity levels and return-to-sport rates than conventional THA cohorts, partly attributable to patient selection (younger, more active patients chose resurfacing) and partly to the stability and preserved biomechanics of the reconstruction. Activities including skiing, cycling, hiking, swimming, and light-to-moderate impact sports are reported by many resurfacing recipients.

The risk profile of hip resurfacing is substantially shaped by the metal-on-metal bearing, which generates cobalt-chromium tribocorrosion products — ions, nanoparticles, and organic metal complexes — that distribute systemically and can cause local and systemic adverse effects. This section covers the regulatory history and clinical risks in detail.

Metal Ion Generation and Tribocorrosion: MoM bearing surfaces generate cobalt and chromium ions through two mechanisms: (1) articulating surface wear during walking (micromotion between the polished ball and socket surfaces), and (2) mechanically assisted crevice corrosion (MACC) at the modular head-neck taper junction, which was identified as a major ion source even in well-positioned implants. Ion release rates depend critically on cup positioning — malpositioning (excessive inclination >55 degrees, retroversion) causes 'edge loading' where the femoral head partially rides over the cup rim rather than fully within it, generating dramatically elevated wear and ion release.

MHRA Safety Alerts (UK, 2010 and 2012): The UK Medicines and Healthcare products Regulatory Agency (MHRA) issued a Medical Device Alert in April 2010 mandating enhanced follow-up for all patients with metal-on-metal hip implants (both resurfacing and large-head MoM THA), including annual clinical review and blood cobalt and chromium ion measurement. A further MHRA alert in June 2012 strengthened the guidance, specifying: whole-blood ion levels above 7 ppb (micrograms per litre) in either cobalt or chromium require urgent investigation with MARS MRI (Metal Artefact Reduction Sequence); symptom-driven imaging should not wait for threshold exceedance; and all MoM hip patients should have an initial ion test within 1 year of surgery regardless of symptoms.

FDA and MAUDE Database: In the US, the FDA Manufacturer and User Facility Device Experience (MAUDE) database contains thousands of adverse event reports for MoM hip devices, documenting ion-related tissue necrosis, pseudotumor formation, metallosis, pain, and implant failure. The FDA issued a Safety Communication in 2013 requiring metal-on-metal total hip system manufacturers to submit premarket approval applications (PMA) — a higher regulatory standard than the 510(k) clearance pathway most used. Several large-head MoM THA systems were subsequently withdrawn from the US market. The BHR remains FDA-cleared under Humanitarian Device Exemption (HDE) pathway, which requires specific institutional reporting and patient registry enrollment.

Adverse Reaction to Metal Debris (ARMD): The umbrella term for the spectrum of local tissue reactions to MoM ion and particle exposure. ARMD manifestations include:

• Pseudotumors: Fluid collections or solid masses in the periprosthetic tissue, ranging from benign reactive bursae to destructive necrotic masses that erode bone and soft tissue. Prevalence of asymptomatic pseudotumors on MARS MRI ranges from 5–30% in different cohorts; symptomatic pseudotumors requiring revision occur in approximately 2–8% of MoM hips at 10 years in large series, with higher rates in women and in malpositoned components.
• Aseptic lymphocyte-dominated vasculitis-associated lesions (ALVAL): A lymphocyte-mediated tissue response to metal particles, causing necrosis of the periprosthetic capsule and tissue.
• Metallosis: Grossly visible black or grey metal staining of the periprosthetic tissues from metal particle deposition, observed intraoperatively during revision surgery.
• Systemic effects: Elevated blood cobalt causes neurological effects at high levels — cardiomyopathy, hypothyroidism, and polycythemia have been reported in patients with very high ion levels (cobalt >20–40 ppb), primarily from failed large-head MoM THA systems rather than well-functioning resurfacing. Renal impairment increases systemic ion accumulation risk.

Femoral Neck Fracture: The most devastating intraoperative and early postoperative complication specific to resurfacing, occurring in 0.5–2% of cases. Risk factors include small femoral head sizes, femoral neck notching during femoral head preparation, varus component malpositioning, femoral head cysts, and osteoporosis. Most femoral neck fractures require urgent revision to conventional THA.

Registry Revision Rates and Gender Disparity: AOANJRR 2023 data shows overall 10-year cumulative revision rates for all hip resurfacing devices of approximately 8–12%, compared to 5–8% for optimally selected conventional THA. Critically, women undergoing MoM resurfacing have 2–3 times the revision rate of men, confirming that resurfacing is inappropriate for female patients in most circumstances. In optimal male patients with BHR components 50 mm or larger, 10-year revision rates approximate those of the best conventional THA.

All patients with metal-on-metal hip resurfacing or large-head MoM THA are subject to mandatory enhanced surveillance protocols due to the known risks of ion-related adverse effects. This surveillance is lifelong and must not be interrupted even if the patient feels well.

MHRA-Mandated Monitoring Protocol (UK): All MoM hip patients in the UK must receive:

• Initial review within 3 months and at 1 year post-surgery
• Annual clinical review thereafter, including hip examination, patient-reported outcome questionnaire, and review of symptoms
• Whole-blood cobalt and chromium ion measurement annually — using a validated laboratory with appropriate blood collection tubes (trace element tubes, EDTA anticoagulant)
• MARS MRI of the affected hip when: blood ion levels exceed 7 ppb in either metal; new or worsening pain develops; abnormal clinical findings (effusion, swelling, reduced range of motion, groin mass); or at any clinical discretion

Blood Ion Thresholds and Interpretation: Normal values for non-implanted individuals are typically below 0.5 ppb for both cobalt and chromium. Acceptable thresholds in MoM hip patients are debated but generally:

• Below 2 ppb: Generally reassuring; continue annual monitoring
• 2–7 ppb: Intermediate — increased surveillance frequency, consider MARS MRI, seek specialist MoM hip review
• Above 7 ppb (either metal): Indicates unacceptable wear or corrosion; urgent MARS MRI and specialist review required; revision surgery should be seriously considered even in asymptomatic patients
• Trend increasing year-on-year: More significant than an isolated value — even values below 7 ppb that are rising consistently warrant closer investigation

MARS MRI: Metal Artefact Reduction Sequence MRI is a specialized imaging protocol that uses MARS software correction to reduce metal-induced signal artefact, enabling visualization of periprosthetic soft tissues including the joint capsule, muscles, and bursae for pseudotumor detection. Standard MRI protocols are inadequate for assessing MoM hip patients. MARS MRI should be performed at centers experienced in MoM hip evaluation.

Rehabilitation and Return to Activity: Recovery from hip resurfacing is broadly similar to conventional THA, with the differences that weight-bearing is sometimes restricted for the first 6 weeks to protect the cemented femoral component, and activity recovery is guided by femoral neck fracture risk monitoring. By 12 weeks, most resurfacing patients are walking normally without aids. Return to recreational sport is typically permitted at 3–6 months; return to high-impact activities at 6–12 months based on surgical judgment.

Revision to Total Hip Arthroplasty: When hip resurfacing fails — due to ARMD, pseudotumor, femoral neck fracture, component loosening, or persistent elevated ions — revision to conventional THA is the treatment. Because the femoral neck is preserved, revision is typically less complex than revision of a failed primary THA with a well-fixed stem: the femoral component is removed, the femoral neck is exposed, and a conventional cementless or cemented femoral stem is implanted, along with a new acetabular cup. The preserved femoral neck and metaphysis provide excellent bone stock for this reconstruction. In most series, revision resurfacing to THA achieves outcomes comparable to primary THA.

Hip resurfacing is generally more expensive than conventional THA due to the premium-priced cobalt-chromium implant components, the specialized surgical expertise required, and the additional costs of mandatory lifelong metal ion monitoring.

United States: BHR resurfacing in the US costs USD 30,000–60,000 all-inclusive (facility, surgeon, anesthesia, and implant), slightly higher than conventional THA due to implant premium and longer operative time. The BHR is FDA-cleared under HDE status, which requires surgeons to be credentialed at participating institutions and patients to be enrolled in the BHR patient registry. Insurance coverage varies widely — some commercial plans cover hip resurfacing as an alternative to THA in young patients; Medicare does not routinely cover it. Patients should obtain prior authorization explicitly confirming resurfacing coverage before scheduling.

United Kingdom: Hip resurfacing is available on the NHS for appropriately selected patients in England, Wales, Scotland, and Northern Ireland. Wait times are similar to conventional THA (12–24 months for elective cases). Private resurfacing at UK private hospitals costs GBP 12,000–18,000 all-inclusive (USD 15,000–22,000), with choice of consultant surgeon and faster access. Some private hospitals and insurers restrict coverage to BHR in male patients due to the established gender disparity in outcomes.

India: Hip resurfacing with the BHR is performed at leading orthopaedic centers in India including Apollo Hospitals, Fortis Bone and Joint Institute, and MIOT International. All-inclusive costs range from USD 6,000–11,000, including BHR implant (imported at international pricing), surgeon fee, hospital stay, and anesthesia. Surgeons performing BHR in India are frequently fellowship-trained in the UK at the Royal Orthopaedic Hospital Birmingham or similar centers. The additional annual cost of blood ion monitoring in India is approximately USD 50–150 per year at private laboratory services.

Ongoing Monitoring Costs: Annual cobalt and chromium blood testing is an additional lifetime cost for all resurfacing patients. In the US, laboratory costs per ion panel range from USD 200–500 depending on the lab and insurance coverage. MARS MRI costs USD 1,500–3,500 per exam in the US; equivalent to a standard MRI with insurance copay in covered patients. Over 20 years of monitoring, the cumulative additional surveillance cost may reach USD 10,000–50,000 — a relevant factor in total lifetime cost comparison with conventional THA.

Cost Comparison with Conventional THA: For most patients — particularly those over 60 years, female patients, or those with smaller femoral head sizes — the premium cost of resurfacing over conventional THA is not justified by the expected incremental benefit. In the specific narrow population of young active males with optimal anatomy for resurfacing, the potential to preserve bone stock for a future revision and achieve high activity levels may justify the premium for appropriately counseled patients.

Given the narrow indication profile and safety monitoring requirements of MoM resurfacing, it is important that patients understand all alternatives before committing to this procedure.

Conventional Total Hip Arthroplasty with Ceramic-on-Polyethylene: For the majority of patients — including all female patients, patients with small femoral heads, those with femoral neck deformity, and those with renal impairment — conventional THA with ceramic-on-highly-crosslinked-polyethylene (CoXLPE) bearing delivers superior safety and equivalent or better long-term survivorship compared to MoM resurfacing. Modern CoXLPE produces near-zero wear without generating systemic metal ions, requires no special blood monitoring, and has 15–20 year survivorship data of 90–95%. Conventional THA with large-head designs (32–36 mm in conventional THA; dual-mobility cups) provides dislocation rates of 0.5–1.5% without the metal-on-metal risks. This is the recommended alternative for nearly all patients who might otherwise consider resurfacing.

Ceramic-on-Ceramic THA: For young, very active male patients who are concerned about long-term wear, ceramic-on-ceramic THA (cobalt-chromium or titanium stem + ceramic head on ceramic liner) provides essentially zero wear and no metal ion generation, with dislocation rates of 1–2% using modern large-head ceramic options. Ceramic fracture risk is approximately 0.01–0.02% with modern BIOLOX delta material. Audible squeaking occurs in 0.5–2% of ceramic-on-ceramic patients — related to fluid film disruption — but is rarely revision-worthy. For young active males who want the best wear performance without metal-on-metal risks, ceramic-on-ceramic THA is an excellent alternative to resurfacing.

Hip Arthroscopy: For patients under 50 with hip pain from femoroacetabular impingement (FAI) and minimal or no arthritic change (Tonnis grade 0–1, joint space preserved >2 mm), hip arthroscopy with FAI correction and labral repair can relieve pain and delay or avoid the need for any hip replacement. Hip arthroscopy is not appropriate when established osteoarthritis is present — it does not address bone-on-bone disease.

For Patients with Existing MoM Implants: Patients who already have metal-on-metal resurfacing or large-head MoM THA implants should not panic — many are functioning well with acceptable ion levels and no ARMD. The appropriate action is to follow the monitoring protocol: annual clinical review with blood ion testing, MARS MRI if triggered by elevated ions or new symptoms, and regular contact with the implanting or monitoring orthopaedic surgeon. Prophylactic revision of a well-functioning MoM hip is not currently recommended solely on the basis of device type; the decision to revise is individualized based on ion levels, imaging findings, symptoms, and patient risk factors. If you are unsure whether your hip monitoring is up to date, contact your orthopaedic surgeon or the hospital where your implant was placed — they are required to maintain a MoM hip register.